中国临床保健杂志2025，Vol.28Issue(6)：763-768,6.DOI:10.3969/J.issn.1672-6790.2025.06.008
阻塞性睡眠呼吸暂停的药物治疗新视角:聚焦肠促胰素
A new perspective on drug therapy for obstructive sleep apnea:focusing on incretin
摘要
Abstract
Obstructive Sleep Apnea(OSA)is an increasingly prevalent global health burden.While continuous positive airway pressure remains the traditional first-line therapy,its efficacy is often limited by suboptimal adherence.Recently,incretin-based therapies,including GLP-1 receptor agonists(GLP-1RA)and dual GIP/GLP-1RA,have emerged as a promising new pharmacologic strategy for OSA management.These agents primarily improve upper airway anatomy through significant weight loss mediated by appetite and feeding regulation.Critically,mounting clinical evidence suggests that these drugs also exert potent pleiotropic effects independent of weight loss,such as anti-inflammation,enhancement of energy metabolism,and favorable fat distribution remodeling.This multifaceted approach targets the complex pathophysiology of OSA,leading to an effective reduction in apnea events.This article reviews the latest clinical advances and key evidence supporting the use of incretin-based drugs for OSA,summarizes their diverse mechanisms of action,and discusses the future challenges and clinical application prospects of this rapidly evolving field.关键词
睡眠呼吸暂停,阻塞性/肠促胰素类/连续气道正压通气/综述Key words
Sleep apnea,obstructive/Incretins/Continuous positive airway pressure/Review引用本文复制引用
张文杰,丁钐,潘琦..阻塞性睡眠呼吸暂停的药物治疗新视角:聚焦肠促胰素[J].中国临床保健杂志,2025,28(6):763-768,6.基金项目
国家科技重大专项(2024ZD0531900,2024ZD0531905) （2024ZD0531900,2024ZD0531905）
北京医院指南专项(BJ-2025-209) （BJ-2025-209）
